PSTV News & Events

Plus Therapeutics announced the appointment of Eric Daniels as chief development officer, effective April 20. Daniels most recently served as chief development officer at Kiora Pharmaceuticals, where he oversaw the company's full development portfolio, including clinical, preclinical, and CMC activities, and worked closely with executive leadership and Kiora's board of directors to define and execute development strategy.

Plus Therapeutics announced that the FDA has granted Orphan Drug Designation to Reyobiq for the treatment of pediatric malignant gliomas. Notably, the FDA granted orphan designation for malignant glioma more broadly than originally requested, encompassing pediatric ependymoma.

Plus Therapeutics announced that the American Medical Association has approved a new, proprietary laboratory analyses current procedural terminology code for its CNSide Cerebrospinal Fluid Tumor Cell Enumeration test. The dedicated billing code, 0640U, effective July 1, establishes a unique reimbursement identifier for the CNSide CSF TCE test, supporting payer claims processing and facilitating broader clinical adoptions as the company continues the U.S. commercial launch of its CNS metastases diagnostic platform.